Navigation Links
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
Date:5/27/2009

/p>

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulatio
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
4. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
5. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
6. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
7. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
8. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
9. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
10. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... created a deicing film for radar domes have now ... for glass. , The new work by Rice ... surfaces from windshields to skyscrapers free of ice and ... , The technology was introduced this month in ... Interfaces . , The material is made of ...
(Date:9/16/2014)... Fresne, President and CEO of Egenix, Inc. is pleased to ... its Scientific Advisory Committee. Dr. Vagner, a graduate ... performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... of health and medical research. He is a Research Director ... France , and at the Gustave Roussy ...
(Date:9/16/2014)... Sept. 16, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... the completion of the Company,s Investor Day in ... its irritable bowel syndrome (IBS) program, including its ... In the keynote presentation, Mark ...
Breaking Biology Technology:Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will,be ... Tuesday, August 5th at 11:30 am Eastern Time., Event: ... Dan Starck, President and CEO ... 11:30 am Eastern Time, Tuesday, August ...
... Researchers at Fred Hutchinson Cancer,Research Center have received ... Genome Research Institute to better understand the genetic,and ... is one of,four U.S. research institutes to receive ... The Hutchinson Center project, led by biostatistician and ...
... MOUNTAINSIDE, N.J., July 17 National Stem,Cell Holding, ... owned,subsidiary Proteoderm, Inc. is exhibiting at the 16th ... in Washington, DC on July,17 -- 19, 2008. ... speak as a,scientific keynote panelist. Dr. Steiner will ...
Cached Biology Technology:CorVel Corporation Announces Earnings Release Webcast 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 3National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine 2
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
(Date:9/15/2014)... for both plants and animals alike. , Understanding just ... lead to the design of better drugs for diabetes ... and vegetables farmers are able to grow. Stanford University ... the cell by piecing together proteins slightly wider than ... To determine the size, shape and orientation of one ...
(Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2
... Each year, millions of monarch butterflies ( Danaus ... to colonize eastern North America, but just how these ... their breeding range in spring has largely remained a ... Guelph led by Prof. Ryan Norris, Department of Integrative ...
... musculus ) happily live wherever there are humans. When ... them. New research published in BioMed Central,s open access ... techniques on modern day and ancestral mouse mitochondrial DNA ... that of Viking invasion. During the Viking age ...
... Calif., March 18, 2012 Autoimmune diseases, such as ... an immune system gone haywire, where the body,s defense ... of a protein called LYP has been implicated in ... has been unknown. Now, in a paper published March ...
Cached Biology News:Study reveals how monarch butterflies recolonize northern breeding range 2The Viking journey of mice and men 2New insight into mechanisms behind autoimmune diseases suggests a potential therapy 2
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
... hydrophobic barrier pen for immunohistochemistry and in ... frozen or paraffin-embedded tissue sections mounted on ... heat-stable, water-repellent barrier that keeps staining reagents ... of reagents when differentially staining two sections ...
Biology Products: